Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neuronetics, Inc.STIM · Entity 6248 | 10% owner | August 13, 2026 | August 17, 2026 |
| Starling Oncology, Inc.STLN · Entity 5327 | 10% owner | August 13, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neuronetics, Inc.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,602,988 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Purchase · Acquired 14,000 · Balance 10,602,988 F1: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.13 tgo $3.17 rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
| Call Option (STIM 19FEB27 $5C)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2027-02-19 | Direct | 0 |
Reported balance
After 2026-08-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-13 · Sale · Disposed 100 · Balance 0 F2: The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.13 tgo $3.17 rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.
F2: The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer.
Starling Oncology, Inc.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,660,858 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Purchase · Acquired 12,000 · Balance 10,660,858 |
| Call Option (STLN 19FEB27 $9C)SEC Table II · derivative / convertible security · Conversion / exercise price $9.00 · Expires 2027-02-19 | Direct | 0 |
Reported balance
After 2026-08-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-13 · Sale · Disposed 100 · Balance 0 F1: The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Airsculpt Technologies, Inc.
Report date April 17, 2026 · Filed April 20, 2026
Section 16 reporting ended · disclosed 2026-04-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,053,761 |
Reported balance
After 2026-04-17 transaction · row 1
1 source rowRow 1 · 2026-04-17 · Purchase · Acquired 40,000 · Balance 7,053,761 F1: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.56, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
| Call Option (AIRS 17APR26 $4C)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2026-04-17 | Direct | 0 |
Reported balance
After 2026-04-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-17 · Other · Disposed 2,004 · Balance 0 F2: These call options expired unexercised on April 17, 2026, as the market price of the underlying common stock was below the exercise price of the options at the time of expiration. No consideration was received by the Reporting Person in connection with this expiration. |
| Call Option (AIRS 17APR26 $5C)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2026-04-17 | Direct | 0 |
Reported balance
After 2026-04-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-17 · Other · Disposed 2,000 · Balance 0 F2: These call options expired unexercised on April 17, 2026, as the market price of the underlying common stock was below the exercise price of the options at the time of expiration. No consideration was received by the Reporting Person in connection with this expiration. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.56, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.
F2: These call options expired unexercised on April 17, 2026, as the market price of the underlying common stock was below the exercise price of the options at the time of expiration. No consideration was received by the Reporting Person in connection with this expiration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 17, 2026 14:13 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 14,000 | $3.16 | $44,240.00 |
DisclosureSEC source: 0000921895-26-002204 · form414528003stim_08172026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,602,988 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.13 tgo $3.17 rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 14:13 UTC | Starling Oncology, Inc. STLN · Entity 5327 | PurchaseCommon Stock | 12,000 | $6.54 | $78,480.00 |
DisclosureSEC source: 0000921895-26-002203 · form414528003stln_08172026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,660,858 Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 14:13 UTC | Neuronetics, Inc. STIM · Entity 6248 | SaleCall Option (STIM 19FEB27 $5C) · Derivative | 100 | $3.21 Strike: $5.00 | $321.00 |
DisclosureSEC source: 0000921895-26-002204 · form414528003stim_08172026.xml · derivative · entry 2 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-02-19 F2 · security: The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 14:13 UTC | Starling Oncology, Inc. STLN · Entity 5327 | SaleCall Option (STLN 19FEB27 $9C) · Derivative | 100 | $6.24 Strike: $9.00 | $624.00 |
DisclosureSEC source: 0000921895-26-002203 · form414528003stln_08172026.xml · derivative · entry 2 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-02-19 F1 · security: The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 13:55 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 18,000 | $5.27 | $94,860.00 |
DisclosureSEC source: 0000921895-26-001852 · form414528003_07222026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,648,858 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $5.27 to $5.28, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| July 14, 2026 Filed Jul 15, 2026 13:33 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 35,000 | $1.78 | $62,300.00 |
DisclosureSEC source: 0000921895-26-001811 · form414528004_07152026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,588,988 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.77 to $1.79, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| July 10, 2026 Filed Jul 13, 2026 15:34 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 15,000 | $5.85 | $87,750.00 |
DisclosureSEC source: 0000921895-26-001798 · form414528001_07132026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,630,858 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $5.82 to $5.90, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 13:31 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 18,000 | $5.02 | $90,360.00 |
DisclosureSEC source: 0000921895-26-001657 · form414528003_06242026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,615,858 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $5.02 to $5.04, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 13:38 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 12,000 | $4.75 | $57,000.00 |
DisclosureSEC source: 0000921895-26-001564 · form414528003_06052026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,579,858 Read SEC document |
| May 20, 2026 Filed May 21, 2026 13:35 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 33,500 | $4.07 | $136,345.00 |
DisclosureSEC source: 0000921895-26-001466 · form414528003_05212026.xml · nonDerivative · entry 2 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,567,858 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $4.05 to $4.10, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| May 19, 2026 Filed May 20, 2026 16:39 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 100,000 | $1.17 | $117,000.00 |
DisclosureSEC source: 0000921895-26-001445 · form414528003stim_05202026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,553,988 Read SEC document |
| May 19, 2026 Filed May 20, 2026 16:25 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 30,000 | $4.09 | $122,700.00 |
DisclosureSEC source: 0000921895-26-001444 · form414528003toi_05202026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,529,358 Read SEC document |
| May 19, 2026 Filed May 21, 2026 13:35 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 5,000 | $4.05 | $20,250.00 |
DisclosureSEC source: 0000921895-26-001466 · form414528003_05212026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,534,358 Read SEC document |
| May 12, 2026 Filed May 13, 2026 12:31 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 475,000 | $1.34 | $636,500.00 |
DisclosureSEC source: 0000921895-26-001259 · form414528003_05132026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,453,988 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.27 to $1.36, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 13:39 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 100,000 | $1.51 | $151,000.00 |
DisclosureSEC source: 0000921895-26-001056 · form414528003_04222026.xml · nonDerivative · entry 2 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,978,988 F2 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.52, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 13:39 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 100,000 | $1.58 | $158,000.00 |
DisclosureSEC source: 0000921895-26-001056 · form414528003_04222026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,878,988 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.56 to $1.59, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| April 17, 2026 Filed Apr 20, 2026 13:16 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | OtherCall Option (AIRS 17APR26 $5C) · Derivative | 2,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0000921895-26-001030 · form414528003_04202026.xml · derivative · entry 3 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2026-04-17 F2 · price: These call options expired unexercised on April 17, 2026, as the market price of the underlying common stock was below the exercise price of the options at the time of expiration. No consideration was received by the Reporting Person in connection with this expiration. Read SEC document |
| April 17, 2026 Filed Apr 20, 2026 13:16 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | OtherCall Option (AIRS 17APR26 $4C) · Derivative | 2,004 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0000921895-26-001030 · form414528003_04202026.xml · derivative · entry 2 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,400 shares Expires 2026-04-17 F2 · price: These call options expired unexercised on April 17, 2026, as the market price of the underlying common stock was below the exercise price of the options at the time of expiration. No consideration was received by the Reporting Person in connection with this expiration. Read SEC document |
| April 17, 2026 Filed Apr 20, 2026 13:16 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCommon Stock | 40,000 | $2.54 | $101,600.00 |
DisclosureSEC source: 0000921895-26-001030 · form414528003_04202026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,053,761 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.56, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| April 14, 2026 Filed Apr 15, 2026 13:35 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCommon Stock | 20,000 | $2.60 | $52,000.00 |
DisclosureSEC source: 0000921895-26-000989 · form414528003_04152026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,013,761 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.59 to $2.61, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 13:03 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 20,000 | $3.10 | $62,000.00 |
DisclosureSEC source: 0000921895-26-000958 · form414528003_04132026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,499,358 Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 13:09 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCommon Stock | 60,000 | $2.93 | $175,800.00 |
DisclosureSEC source: 0000921895-26-000944 · form414528003_04082026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,993,761 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.91 to $2.94, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| April 03, 2026 Filed Apr 6, 2026 13:34 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCommon Stock | 90,000 | $2.82 | $253,800.00 |
DisclosureSEC source: 0000921895-26-000915 · form414528003_04062026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,933,761 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.67 to $3.00, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 30, 2026 Filed Mar 30, 2026 23:41 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 385,442 | $1.25 | $481,802.50 |
DisclosureSEC source: 0000921895-26-000835 · form414528003_03302026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,778,988 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.26, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. F2 · balance_after: This amount corrects a clerical error in the Reporting Person's Form 4 previously filed on March 30, 2026, in which the number of shares beneficially owned by the Reporting Person was under-reported by 270 shares. Read SEC document |
| March 27, 2026 Filed Mar 30, 2026 13:38 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 27,429 | $2.96 | $81,189.84 |
DisclosureSEC source: 0000921895-26-000823 · form414528003toi_03302026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,479,358 Read SEC document |
| March 27, 2026 Filed Mar 30, 2026 13:37 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 500,000 | $1.35 | $675,000.00 |
DisclosureSEC source: 0000921895-26-000822 · form414528003stim_03302026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,393,276 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.28 to $1.41, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 13:34 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 50,000 | $3.15 | $157,500.00 |
DisclosureSEC source: 0000921895-26-000814 · form414528003toi_03272026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,451,929 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.11 to $3.19, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 13:33 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 25,000 | $1.44 | $36,000.00 |
DisclosureSEC source: 0000921895-26-000813 · form414528003stim_03272026.xml · nonDerivative · entry 2 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,893,276 Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 13:33 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 125,000 | $1.40 | $175,000.00 |
DisclosureSEC source: 0000921895-26-000813 · form414528003stim_03272026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,868,276 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.38 to $1.42, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 24, 2026 Filed Mar 25, 2026 13:33 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 125,000 | $3.11 | $388,750.00 |
DisclosureSEC source: 0000921895-26-000796 · form414528003_03252026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,401,929 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.04 to $3.15, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 17:43 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCall Option (AIRS 17APR26 $5C) · Derivative | 2,000 | $0.33 Strike: $5.00 | $660.00 |
DisclosureSEC source: 0000921895-26-000802 · form414528003air_03252026.xml · derivative · entry 5 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 200,000 shares Expires 2026-04-17 F5 · price: The price reported in Column 8 is a weighted average price, rounded to the nearest cent. These call options were purchased in multiple transactions at prices ranging from $0.30 to $0.35, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of call options purchased at each separate price such call options were purchased. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 17:43 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCall Option (AIRS 17APR26 $4C) · Derivative | 2,004 | $0.50 Strike: $4.00 | $1,002.00 |
DisclosureSEC source: 0000921895-26-000802 · form414528003air_03252026.xml · derivative · entry 4 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,004 Underlying: Common Stock · 200,400 shares Expires 2026-04-17 F4 · price: The price reported in Column 8 is a weighted average price, rounded to the nearest cent. These call options were purchased in multiple transactions at prices ranging from $0.45 to $0.55, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of call options purchased at each separate price such call options were purchased. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 17:43 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | SaleCall Option (AIRS 17APR26 $2C) · Derivative | 6,547 | $1.13 Strike: $2.00 | $7,398.11 |
DisclosureSEC source: 0000921895-26-000802 · form414528003air_03252026.xml · derivative · entry 3 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 654,700 shares Expires 2026-04-17 F2 · security: The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. F3 · price: The price reported in Column 8 is a weighted average price, rounded to the nearest cent. These call options were sold in multiple transactions at prices ranging from $1.00 to $1.20, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of call options sold at each separate price such call options were purchased. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 17:43 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCall Option (AIRS 17APR26 $2C) · Derivative | 2,255 | $1.30 Strike: $2.00 | $2,931.50 |
DisclosureSEC source: 0000921895-26-000802 · form414528003air_03252026.xml · derivative · entry 2 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,547 Underlying: Common Stock · 225,500 shares Expires 2026-04-17 Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 17:43 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCommon Stock | 50,000 | $2.91 | $145,500.00 |
DisclosureSEC source: 0000921895-26-000802 · form414528003air_03252026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,843,761 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.84 to $2.91, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 13:34 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 169,472 | $1.41 | $238,955.52 |
DisclosureSEC source: 0001193805-26-000308 · e665271_4-stim.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,743,276 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.36 to $1.44, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 13:33 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCommon Stock | 40,000 | $2.77 | $110,800.00 |
DisclosureSEC source: 0001193805-26-000307 · e665270_4-airs.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,793,761 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.73 to $2.79, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 13:33 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 25,000 | $3.35 | $83,750.00 |
DisclosureSEC source: 0001193805-26-000306 · e665269_4-toi.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,276,929 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.33 to $3.35, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 13:33 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCommon Stock | 77,702 | $2.64 | $205,133.28 |
DisclosureSEC source: 0000921895-26-000752 · form414528003air_03202026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,753,761 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.49 to $2.70, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 12:51 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 450,000 | $1.33 | $598,500.00 |
DisclosureSEC source: 0000921895-26-000751 · form414528003sti_03202026.xml · nonDerivative · entry 2 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,573,804 F2 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.48, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 12:51 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 607,400 | $1.35 | $819,990.00 |
DisclosureSEC source: 0000921895-26-000751 · form414528003sti_03202026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,123,804 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.33 to $1.37, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 17, 2026 Filed Mar 17, 2026 23:40 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 75,000 | $3.42 | $256,500.00 |
DisclosureSEC source: 0000921895-26-000712 · form414528003_03172026.xml · nonDerivative · entry 3 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,251,929 F3 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.39 to $3.49, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 14:36 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCommon Stock | 83,000 | $2.56 | $212,480.00 |
DisclosureSEC source: 0001193805-26-000283 · e665258_4-airsculpt.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,676,059 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.43 to $2.70, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. F2 · balance_after: This amount corrects a clerical error in the Reporting Person's Form 4 filed on March 16, 2025, in which the number of shares beneficially owned by the Reporting Person was under-reported by 1,000 shares. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 14:36 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 531,000 | $1.16 | $615,960.00 |
DisclosureSEC source: 0001193805-26-000282 · e665257_4-neuronetics.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,516,404 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $0.91 to $1.31, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 16, 2026 Filed Mar 16, 2026 22:43 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCommon Stock | 105,848 | $2.43 | $257,210.64 |
DisclosureSEC source: 0000921895-26-000696 · form414528003_03162026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,592,059 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.93 to $2.79, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 23:40 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 60,985 | $3.29 | $200,640.65 |
DisclosureSEC source: 0000921895-26-000712 · form414528003_03172026.xml · nonDerivative · entry 2 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,176,929 F2 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.43, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 23:40 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 263,000 | $2.92 | $767,960.00 |
DisclosureSEC source: 0000921895-26-000712 · form414528003_03172026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,115,944 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.77 to $3.34, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:30 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCommon Stock | 88,000 | $2.15 | $189,200.00 |
DisclosureSEC source: 0000921895-26-000668 · form414528003_03112026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,486,211 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.11 to $2.25, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 06, 2026 Filed Mar 9, 2026 12:40 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCommon Stock | 45,600 | $2.00 | $91,200.00 |
DisclosureSEC source: 0000921895-26-000638 · form414528003_03092026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,398,211 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.96 to $2.09, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 23:58 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCommon Stock | 30,000 | $1.87 | $56,100.00 |
DisclosureSEC source: 0000921895-26-000613 · form414528003_03042026.xml · nonDerivative · entry 2 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,352,611 F2 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.86 to $1.88, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.